OvaScience, Inc., a fertility company, discovers, develops, and commercializes fertility treatment options for women and families struggling with infertility worldwide.
The last earnings update was 28 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
OvaScience. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
OvaScience's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OvaScience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare OvaScience's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare OvaScience's earnings growth to the Germany market average as no estimate data is available.
Unable to compare OvaScience's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if OvaScience is high growth as no earnings estimate data is available.
Unable to determine if OvaScience is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
OvaScience's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Christopher A. Kroeger, also known as Chris, M.D., MBA has been Chief Executive Officer and Director of OvaScience, Inc. since September 1, 2017 and also serves its President and Secretary. Dr. Kroeger has been a Partner at The Aurora Funds, Inc., since 2007. Dr. Kroeger was a Principal of HyperBranch Medical Technology, Inc. Dr. Kroeger served as Chief Executive Officer and President of Cardioxyl Pharmaceuticals, Inc. since 2008. His professional experience includes as an Associate in corporate development at Genzyme, where he performed scientific and clinical due diligence, market research and financial modeling. Dr. Kroeger has extensive experience leading, building and advising development-stage therapeutic and medical device companies and has a strong clinical and research background as a practicing physician and scientist. Dr. Kroeger has led or co-led syndicated investments. He has significant basic science research experience primarily in signal transduction, including work on the molecular biology and genetics of apoptosis and the transcriptional regulation of Interleukin-2 in human T-cells. He has over seven years of clinical experience in both academic and community hospital practices. Dr. Kroeger also spent four years as a General Surgery Resident at Brigham and Women's Hospital and Harvard Medical School where he was involved in the medical and surgical care of transplant, trauma, vascular, cardiac and general surgical patients. He has over seven years of clinical experience in both academic and community hospital practices and is a licensed physician in North Carolina. Dr. Kroeger also worked at Arthur D. Little in Decision Resources, performing industry analysis for the biotechnology and pharmaceutical industries. He has been a Director of ParinGenix Inc. since August 2006, Cantex Pharmaceuticals, Inc., since August 2006, CardioFocus, Inc. since April 2006. He serves as an Observer on the Boards of Aldagen, Argos, Metastatix and Regado. Dr. Kroeger is also serves on the Boards of the Johns Hopkins Technology Alliance and The University of Maryland Baltimore Commercialization Advisory Board. He served as a Director of The Council for Entrepreneurial Development (CED). He served as Director at Cardioxyl Pharmaceuticals since 2006, Neotropix, Inc., Aurora Funds portfolio companies and HyperBranch Medical Technology Inc. since January 25, 2005. He served as a Director of Regado Biosciences, Inc. He has worked with over a dozen biotechnology and medical device companies during his career. Dr. Kroeger holds an M.D. degree from Stanford University School of Medicine in 1996, a M.B.A. degree from Harvard Business School in June 2003 and a B.A. degree in Biology from Harvard University and his Residency in General Surgery at the Brigham and Women’s Hospital, an affiliate of Harvard Medical School.
Insufficient data for Chris to compare compensation growth.
Chris's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the OvaScience management team is less than 2 years, this suggests a new team.
Co-Founder & Advisor
Senior VP of Finance & Treasurer
Co-Founder and Advisor
Vice President of Strategy & Operations
Chief Scientific Officer
Director of Corporate Communications
Senior Vice President of Corporate Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the OvaScience board of directors is about average.
OvaScience, Inc., a fertility company, discovers, develops, and commercializes fertility treatment options for women and families struggling with infertility worldwide. Its patented technology is based on the discovery about the existence of egg precursor (EggPC) cells to transform the treatment landscape for women’s fertility. The company offers various fertility treatment options, including OvaPrime treatment to restore a woman’s egg production by isolating a woman’s own EggPC cells within her ovary to mature in vivo into healthy and fertilizable eggs; OvaTure treatment to mature EggPC cells into fertilizable eggs in vitro or outside the body by eliminating the need for hormone stimulation; and AUGMENT treatment to enhance the fertilization and pregnancy rates by using mitochondria from a woman’s own EggPC cells. It also provides OvaXon for the prevention of inherited diseases for human and animal health. The company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011. OvaScience, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.